50877-45-7

Basic information

• Product Name: 4-bromo-3-methyl-1-phenyl-1H-pyrazole
• Synonyms: 4-bromo-3-methyl-1-phenyl-1H-pyrazole
• CAS NO: 50877-45-7
• Molecular Weight: 237.099
• Mol File: 50877-45-7.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 4-bromo-3-methyl-1-phenyl-1H-pyrazole(CAS DataBase Reference)
• NIST Chemistry Reference: 4-bromo-3-methyl-1-phenyl-1H-pyrazole(50877-45-7)
• EPA Substance Registry System: 4-bromo-3-methyl-1-phenyl-1H-pyrazole(50877-45-7)

Safety Data

• Hazardous Substances Data: 50877-45-7(Hazardous Substances Data)

Upstream product

• 69413-02-1 1-(4-Bromo-3-methyl-pyrazol-1-yl)-ethanone 
• 98-80-6 phenylboronic acid 
• 13808-64-5 4-bromo-3-methyl-1H-pyrazole 
• 89-25-8 edaravone 
• 1128-54-7 3-methyl-1-phenyl-1H-pyrazole 
• 7726-95-6 bromine 
• 64-19-7 acetic acid 

Downstream Products

• 1469884-31-8 3-methyl-1-phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole 
• 18093-92-0 3-methyl-1-phenyl-1H-pyrazole-4-carbonitrile 
• 91211-33-5 4,5-Dibrom-3-methyl-1-phenyl-pyrazol 

Relevant articles and documents

Predictable site-selective functionalization: Promoter group assistedpara-halogenation ofN-substituted(hetero)aromatics under metal-free condition

Herein, regioselectivepara-C-H halogenation ofN-pyrimidyl (hetero)aromatics through SEAr (electrophilic aromatic substitution) type reaction is disclosed. SEAr type reaction has been utilized for the C5-bromination of indolines (para-selective) withN-bromosuccinimide under metal and additive-free conditions in good to excellent yields. The developed methodology is also applicable for iodination and challenging chlorination. The pyrimidyl group is identified as a reactivity tuner that also controls the regioselectivity. The present method is also applicable for selective halogenation of aniline, pyridine, indole, oxindole, pyrazole, tetrahydroquinoline, isoquinoline, and carbazole. DFT studies such as Fukui nucleophilicity and natural charge maps also support the observedp-selectivity. Post-functionalization of the title compound into the corresponding arylated, olefinated, and dihalogenated products is achieved in a one-pot, two-step fashion. Late-stage C-H bromination was also executed on drug/natural molecules (harmine, etoricoxib, clonidine, and chlorzoxazone) to demonstrate the applicability of the developed protocol.

HETEROARYL COMPOUNDS AND PHARMACEUTICAL APPLICATIONS THEREOF

The present invention provides herein is a heteroaryl compound or a stereoisomer, a geometric isomer, a tautomer, a racemate, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, as well as a pharmaceutical composition containing the compound disclosed herein. The present invention also provides herein is use of the compound or the pharmaceutical composition thereof disclosed herein in the manufacture of a medicine for treating autoimmune diseases or proliferative diseases.